Registration
Advertiser Disclosure

Biotech research and drug discovery by Nurix Therapeutics

Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study
  • Artem Shendetskii
  • Yesterday
Nurix Therapeutics advances CLL therapy with DAYBREAK-CLL-201 study
Nurix Therapeutics has launched its DAYBREAK-CLL-201 clinical trial to evaluate bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The study ...
Nurix Therapeutics surges with new oral BTK degrader bexobrutideg momentum in CLL treatment
  • Ashutosh Sureka
  • 14.07.2026
Nurix Therapeutics surges with new oral BTK degrader bexobrutideg momentum in CLL treatment
Nurix Therapeutics is seeing growing momentum for BTK degradation strategies in the treatment of relapsed and refractory chronic lymphocytic leukemia (CLL). In a recent interview with OncLive, ...
Nurix Therapeutics forges strategic partnership with Roche to accelerate bexobrutideg program
  • Igor Krasulya
  • 10.07.2026
Nurix Therapeutics forges strategic partnership with Roche to accelerate bexobrutideg program
Nurix Therapeutics reported its financial results for the second quarter of 2026, emphasizing significant advancement in its development pipeline. The company announced a new global ...
Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies
  • Andreas Kristo
  • 08.06.2026
Nurix Therapeutics enters partnership with Roche to advance targeted protein degradation therapies
Nurix Therapeutics has announced a strategic partnership with Roche to develop first-in-class targeted protein degradation therapies aimed at patients with significant unmet medical needs. This ...
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU
  • Eugene Komchuk
  • 15.05.2026
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU
Nurix Therapeutics announced the presentation of new preclinical and Phase 1 translational data focused on its investigational therapy, bexobrutideg (NX-5948), for chronic spontaneous urticaria ...
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026
  • Andreas Kristo
  • 12.05.2026
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026
Nurix Therapeutics announced that updated efficacy and safety data from its ongoing Phase 1a b clinical trial of the BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic ...
Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference
  • Ashutosh Sureka
  • 23.03.2026
Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference
Nurix Therapeutics announced plans to present multiple research abstracts, including an oral presentation detailing preclinical data from several of its degrader programs, at the upcoming AACR26 ...
Nurix Therapeutics presents data on BTK degrader at ASH meeting
  • Mikhail Vnuchkov
  • 05.11.2025
Nurix Therapeutics presents data on BTK degrader at ASH meeting
Nurix Therapeutics has announced the presentation of data from its clinical and translational studies on the BTK degrader, bexobrutideg (NX-5948). This significant development will be showcased ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR